

Danish trial demonstrates benefits of dual-chamber pacing in treating sick sinus syndrome

August 31 2010

DANPACE, a Danish multicentre randomised trial comparing single lead atrial and dual chamber pacing in patients with sick sinus syndrome, concludes that dual chamber pacing, which was associated with lower rates of atrial fibrillation and re-operation, "should be the preferred pacing mode".

Behind the conclusion lies a 20-site study of 1415 subjects with sick sinus syndrome (a variety of arrhythmias caused by a malfunction of the sinus node, the heart's principal pacemaker) referred for their first pacemaker implantation. Pacemakers are routinely used to treat patients suffering from sick sinus syndrome.

The patients were randomised equally to single-lead atrial or dual-chamber pacemakers* and their progress followed for a mean of 6.4 years, producing over 7000 operational years of evidence. Results showed that all-cause [mortality rates](#) were similar in both groups, 29.6% in the single-lead atrial pacemaker group and 27.3% in the dual chamber group. However, the prevalence of paroxysmal atrial fibrillation was lower in the dual chamber group than in the single-lead group (HR 0.79, $p=0.024$), with significantly fewer dual chamber patients requiring pacemaker re-operation during follow-up (HR 0.50, p

Citation: Danish trial demonstrates benefits of dual-chamber pacing in treating sick sinus

syndrome (2010, August 31) retrieved 10 April 2024 from
<https://medicalxpress.com/news/2010-08-danish-trial-benefits-dual-chamber-pacing.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.